Analysts Conflicted on These Healthcare Names: Eagle Pharmaceuticals (NASDAQ: EGRX) and Ascendis Pharma (NASDAQ: ASND)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eagle Pharmaceuticals (NASDAQ: EGRX) and Ascendis Pharma (NASDAQ: ASND).

Eagle Pharmaceuticals (NASDAQ: EGRX)

Mizuho Securities analyst Irina Rivkind Koffler reiterated a Sell rating on Eagle Pharmaceuticals (NASDAQ: EGRX) today and set a price target of $37. The company’s shares opened today at $62.44.

Rivkind Koffler wrote:

“We attribute the miss to lower revenues and higher COGS. Eagle previously announced that it plans to initiate another pivotal trial of Ryanodex in exertional heat stroke (EHS) at the Hajj pilgrimage in August. We view this initiative as largely unproductive because identifying appropriate patients and trial execution could prove challenging yet again. However, enrollment in the fulvestrant trial was faster than expected (data could be a catalyst in the coming months) and Eagle has advanced one of its ANDA filings, which are slight positives to the story. In the past week we saw announcements that two senior executives (Chief Scientific Officer and General Counsel) have left Eagle, which we believe bodes poorly for the future outlook of the company. We reiterate our Underperform rating on the stock and will update thoughts after the call. We summarize 4Q:17 performance below.”

According to TipRanks.com, Koffler is a 5-star analyst with an average return of 13.4% and a 48.2% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Apricus Biosciences Inc, and Pacira Pharmaceuticals.

Eagle Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $58.

Ascendis Pharma (NASDAQ: ASND)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Ascendis Pharma (NASDAQ: ASND), with a price target of $67. The company’s shares opened today at $61.37, close to its 52-week high of $63.69.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 7.5% and a 40.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Currently, the analyst consensus on Ascendis Pharma is Strong Buy and the average price target is $59.25, representing a -3.5% downside.

In a report issued on February 20, J.P. Morgan also maintained a Buy rating on the stock with a $60 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.